Documentos relacionados

1. Trispecific antibodies offer a third way forward for anticancer immunotherapy.
2. Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations.
3. Immune Factors, Immune Cells and Inflammatory Diseases.
4. (SUMO)-wrestling with rituximab.
5. An outlook on the target-based molecular mechanism of phytoconstituents as immunomodulators.
6. Small-molecule modulators of tumor immune microenvironment.
7. [Analysis of the interrelation between immune factors and inflammatory markers, and the course of chronic heart failiure in patients with rheumathoid arthritis].
8. Nanocarriers for effective delivery: modulation of innate immunity for the management of infections and the associated complications.
9. Next-generation antibody-based therapies in neurology.
10. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study.